Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials.

Innocent Gerald AsiimweSudeep P PushpakomRichard M TurnerRuwanthi Kolamunnage-DonaAndrea L JorgensenMunir Pirmohamed

Published in: British journal of clinical pharmacology (2022)

Moderate- to high-certainty RCT evidence suggests that cardiovascular drugs such as ACEIs/ARBs are not associated with poor COVID-19 outcomes, and should therefore not be discontinued. These cardiovascular drugs should also not be initiated to treat or prevent COVID-19 unless they are needed for an underlying currently approved therapeutic indication.

Keyphrases

coronavirus disease
sars cov
respiratory syndrome coronavirus
type diabetes
metabolic syndrome
adipose tissue
weight loss